Endo Pharmaceuticals Holdings (ENDP) Tops Q4 EPS by 7c, Reaffirms Outlook

February 28, 2013 4:13 PM EST Send to a Friend
Endo Pharmaceuticals Holdings (NASDAQ: ENDP) reported Q4 EPS of $1.62, $0.07 better than the analyst estimate of $1.55. Revenue for the quarter came in at $801.1 million versus the consensus estimate of $807.98 million. Endo Pharmaceuticals Holdings reaffirmed FY2013 guidance.

For earnings history and earnings-related data on Endo Pharmaceuticals Holdings (ENDP) click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance

Related Entities

Earnings

Add Your Comment